William Oh, MD: Biggest Considerations for Elderly Patient Population
What are the biggest considerations and concerns in an elderly patient?
CASE: Metastatic Prostate Cancer (Part 1)
Stanley S is an 83-year-old Caucasian male whose past medical history includes diagnosis of adenocarcinoma of the prostate in 2012 with no evidence of metastasis. At the time, he was started on bicalutamide and his serum PSA levels subsequently decreased to 1.2 ng/ml.
During his most recent follow-up exam, the patient complained of intermittent back pain and increasing fatigue.
- His serum PSA level is 56.9 ng/ml and his alkaline phosphatase is 258 U/L
- CT scan shows enlarged lumbar bone metastasis with associated soft tissue component, as well as symptomatic nodes with lumbar bone metastases
- Biopsies of the prostate and transrectal ultrasound reveal the prostate is 42 grams
- Ten of 14 cores are positive for prostate cancer for a Gleason score of 8 (4 + 4)
- His ECOG performance status score is a 2
Novel Frontline Treatments Add Layer of Complexity in Urothelial Carcinoma
January 2nd 2025The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer and nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.
Read More
Cusnir Explores Impact of ARANOTE Data on ARPI Plus ADT Use in mHSPC
December 31st 2024During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they fit into the treatment paradigm for patients with metastatic hormone-sensitive prostate cancer.
Read More
